599 results on '"Stichel, Damian"'
Search Results
52. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution
53. Molecular characterization of medulloblastomas with extensive nodularity (MBEN)
54. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience
55. DNA methylation-based reclassification of olfactory neuroblastoma
56. Data from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
57. Data from Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients
58. Supplementary Table S4 from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
59. Supplementary Figures S1-S8 from Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients
60. Supplementary Data - Tables from Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients
61. Suppl. Figure Legends from Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients
62. Supplementary Data - Materials and Methods from Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients
63. Supplementary Data from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
64. Table S6 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
65. Figure S7 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
66. Supplementary Legend from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
67. Clinical implementation of integrated molecular-morphologic risk prediction for meningioma
68. Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification (Acta Neuropathologica, (2023), 145, 1, (49-69), 10.1007/s00401-022-02516-2)
69. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities
70. Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype
71. Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
72. Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma
73. PATH-46. COMPUTATIONAL HISTOPATHOLOGY INFORMED RAPID TARGETED NANOPORE SEQUENCING ENABLES AFFORDABLE NEXT DAY REPORTING OF COMPREHENSIVE MOLECULAR MARKERS FOR CNS TUMOUR DIAGNOSTICS
74. Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature
75. Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types
76. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas
77. Abstract 2491: Molecular and clinical characterization of the new WHO entity ‘Astroblastoma, MN1 altered’ and its molecular subgroups
78. RARE-15. Astroblastoma, MN1 altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners BEND2 and CXXC5
79. PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study
80. OTHR-41. Amplification of the PLAG family genes – PLAGL1 and PLAGL2 – is a key feature of a novel embryonal CNS tumor type
81. ETMR-06. Molecular and clinical characteristics of CNS tumors withBCOR(L1) fusion/internal tandem duplication
82. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma
83. Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
84. Oligosarcomas, IDH‑mutant are distinct and aggressive
85. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
86. Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
87. Additional file 3 of Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
88. Additional file 5 of Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
89. Additional file 6 of Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
90. Additional file 4 of Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
91. An individual-based model for collective cancer cell migration explains speed dynamics and phenotype variability in response to growth factors
92. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
93. Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
94. Oligosarcomas, IDH-mutant are distinct and aggressive
95. PATH-48. RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY
96. PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE
97. PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED
98. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary
99. Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
100. Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.